The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use has recommended a conditional marketing authorization for Vijoice (alpelisib, Novartis) for the treatment of patients with severe PIK3CA-related overgrowth spectrum (PROS) disorders. Vijoice is indicated for the treatment of adults and children aged 2 years and older with severe or life-threatening manifestations of …
Read More
EMA Backs First Drug for Severe Overgrowth Disorders
